Verve Therapeutics Inc
Company Profile
Business description
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
Contact
201 Brookline Avenue
Suite 601
BostonMA02215
USAT: +1 617 603-0070
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
274
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,576.60 | 46.80 | 0.55% |
| CAC 40 | 7,853.47 | 16.68 | 0.21% |
| DAX 40 | 23,695.59 | 168.58 | 0.72% |
| Dow JONES (US) | 42,322.75 | 271.69 | 0.65% |
| FTSE 100 | 8,633.75 | 48.74 | 0.57% |
| HKSE | 23,262.80 | 190.36 | -0.81% |
| NASDAQ | 19,112.32 | 34.49 | -0.18% |
| Nikkei 225 | 37,734.00 | 21.51 | -0.06% |
| NZX 50 Index | 12,791.30 | 89.52 | -0.69% |
| S&P 500 | 5,916.93 | 24.35 | 0.41% |
| S&P/ASX 200 | 8,341.60 | 44.10 | 0.53% |
| SSE Composite Index | 3,363.32 | 17.50 | -0.52% |